|
|
Volumn 16, Issue 5, 2004, Pages 381-382
|
|
ECF in gastric cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
EPIRUBICIN;
FLUOROURACIL;
ANTINEOPLASTIC AGENT;
ADULT;
AGED;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GRADING;
CANCER PATIENT;
CARDIOTOXICITY;
CLINICAL ARTICLE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
ESOPHAGEAL ADENOCARCINOMA;
GASTROESOPHAGEAL ADENOCARCINOMA;
HUMAN;
LETTER;
MULTIPLE CYCLE TREATMENT;
NEUTROPENIA;
PATIENT SELECTION;
PRIORITY JOURNAL;
RETREATMENT;
STOMACH ADENOCARCINOMA;
STOMACH CANCER;
SURVIVAL RATE;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
WORLD HEALTH ORGANIZATION;
ADENOCARCINOMA;
CASE REPORT;
COMPARATIVE STUDY;
MIDDLE AGED;
PROGNOSIS;
STOMACH TUMOR;
UNITED KINGDOM;
ADENOCARCINOMA;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CISPLATIN;
EPIRUBICIN;
FLUOROURACIL;
GREAT BRITAIN;
HUMANS;
MIDDLE AGED;
PROGNOSIS;
STOMACH NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 16544369885
PISSN: 09366555
EISSN: 14332981
Source Type: Journal
DOI: 10.1016/j.clon.2004.05.006 Document Type: Letter |
|
Times cited : (1)
|
|
References (5)
|
